Form 8-K · Current Report · Filed 2025-01-13
Danaher CEO to Discuss Fourth Quarter 2024 Performance
Danaher Corporation announced that its CEO will comment on the Company's estimated financial performance for the fourth quarter of 2024, with revenues anticipated to increase in the low-single digit percent range year-over-year and non-GAAP core revenue expected to be essentially flat.
- Filer
- Danaher Corporation DHR · NYSE
- Filed
- Accession
- 0000313616-25-000002
- CIK
- 0000313616
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
A press release and presentation slides were furnished as part of the report.
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$235.07
Next session
+1.1%
Since filing
-17.1%
Latest close
$194.98
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from DHR reporting the same item, with the next session's move:
Exhibits (2)
About Danaher Corporation
Danaher Corporation is a globally recognized science and technology company specializing in the development, design, and manufacturing of diverse industrial and healthcare products. With a primary focus on innovations in diagnostics, life sciences, dental, and environmental and applied solutions, Danaher serves a multitude of industries and market sectors. Its cutting-edge diagnostic equipment aids medical professionals in delivering precise healthcare, while its life sciences tools and technologies propel biomedical research and development. The company's environmental solutions also play a key role in enhancing water quality analysis and management. Headquartered in Washington, D.C., Danaher is renowned for its strong operational culture exemplified by the Danaher Business System (DBS), which emphasizes continuous improvement and sustainable innovation. This approach has solidified Danaher's presence and influence in both developing specialized solutions and improving efficiency across global markets. The company's strategic acquisitions and consistent focus on innovation have positioned it as a leader in delivering essential solutions that drive significant improvements for healthcare, research, and industrial clients.
Never miss another DHR filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.